|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/573 | |
| A61K 39/395 | |||
| C07K 16/28 |
| (11) | Number of the document | 3228315 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17159560.6 |
| Date of filing the European patent application | 2011-10-27 | |
| (97) | Date of publication of the European application | 2017-10-11 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-25 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 412229 P | 2010-11-10 | US |
| (72) |
ZUGMAIER, Gerhard, DE
NAGORSEN, Dirk, DE
SCHEELE, Juergen, DE
|
| (73) |
Amgen Research (Munich) GmbH,
Staffelseestrasse 2, 81477 München,
DE
|
| (54) | PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS |
| PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS |